Selling or handing over your pharmacy in France: why the market has changed and how to prepare

For decades, handing over a French community pharmacy (officine) followed a simple pattern: a retiring owner sold the business to a young graduate, financed by their bank on the basis of revenue, and the green cross changed hands without anything changing for the neighbourhood. This model still exists, but it now describes only part of the transactions. In a few years, practising through a company has become the norm, partnerships have multiplied, established owners buy a second or third pharmacy through a holding, buying groups and banners structure the commercial offer, and the number of pharmacies falls every year.

At the same time, pharmacy economics have shifted. Remuneration depends less on the price of packs and more on dispensing fees and new services, margins have eroded over ten years and gaps between pharmacies have widened. Since a pharmacy is both a regulated retail business and a local healthcare provider, continuity of the team and service matters as much as the figures. For an owner thinking about selling, taking on partners or merging, these changes alter the nature of buyers, the timetable to anticipate and the way to prepare the business.

A network of 20,000 pharmacies that is shrinking

France had 20,242 pharmacies on 1 January 2024, a network in continuous decline since the mid-2000s. ¹ The trend is accelerating: 260 closures recorded in 2024 and around 300 in 2025, some without a buyer, while towns lose their last pharmacy each year. ^2,3 Over 2020-2024, the joint mission of the General Inspectorate of Social Affairs (IGAS) and the General Inspectorate of Finance (IGF) counted 1,036 closures, 211 of them the last pharmacy in their town. ¹ Some of these closures result from a merger or restructuring; the rest are pharmacies that found no buyer or were no longer viable.

The sector remains solid overall. Median pharmacy revenue reached €1.9 million in 2023 and network remuneration on reimbursed products exceeded €8 billion in 2024 according to the IGAS-IGF mission. ¹ Dispensing reimbursed medicines is a recurring activity, little affected by the economy and backed by public funding, which explains banks' lasting confidence. But this solidity hides falling profitability: between 2013 and 2023, pharmacies' EBITDA fell 11% and median profitability relative to revenue fell from 8.6% to 5.6%, with a sharper decline in rural areas. ¹ Disparities between shopping centre, town centre and rural pharmacies have never been so wide.

The transaction market remains active but is slowly contracting: the specialist lender Interfimo counts 1,407 pharmacy transfers in 2025, down 2.5% year on year, a transfer rate of 73 per 1,000 pharmacies. ⁴ Business sales represent 57% of transactions and share sales 43%, a sign that practising through a professional practice company (SEL) has become the majority in successions. ⁴

The six drivers of restructuring

Concentration of the pharmacy network is not cyclical. It results from factors that reinforce one another.

Owner demographics. Pharmacy owners now represent only 31.6% of the 75,731 pharmacists registered with the professional order in 2025, and their number has fallen 11.6% in ten years while that of employed pharmacists rose 10.3%. ^5,6 The number of pharmacists over 66 has doubled over the period. ⁵ Many owners who set up in the 1990s are reaching succession age just as candidates, aged 35 on average at their first installation, prefer to partner rather than take over alone: in 53% of first-installation files financed by Interfimo in 2025, the buyer set up with at least one partner. ⁴
The shift of remuneration to fees and services. At the end of 2024, dispensing fees represented 48% of pharmacy remuneration on reimbursed products, against 19% for the regressive margin. ¹ Add vaccination, rapid diagnostic tests for sore throat and cystitis, pharmaceutical consultations, screening and first-line care schemes extended by the 2026 social security financing act. These services value the team, pharmacist time and counter organisation rather than pack volume. They require suitable premises, trained staff and tools, investments more easily amortised in a large pharmacy or within a group of pharmacies.
Margin pressure and the weight of expensive medicines. Medicines with a manufacturer price above €1,930 account for only 0.09% of volume but nearly a quarter of reimbursed revenue, and their revenue has grown 74% in five years. ¹ They inflate revenue without inflating margin, tie up cash and distort performance. At the other end, generic price cuts and supply shortages weigh on counter profitability. The January 2026 IGAS-IGF report recommends fully decoupling remuneration from prices and volumes, which will reshuffle the cards between pharmacies again. ¹
Digitalisation and logistics. Robotic stock management, automated ordering, online booking for services, omnichannel services, shared medical records: these tools free pharmacist time for advice and new services, but represent significant investments a standalone pharmacy struggles to amortise.
Structuring by buying groups and banners. Around 94% of owners belong to a buying group according to the national collective of pharmacy groups, and more than one pharmacy in seven now displays one of the seven main banners listed by LSA (Aprium, Elsie Santé, Giphar, Pharmacie Lafayette, Leadersanté, Pharmabest, Totum). ⁷ The groups themselves are merging to carry weight with manufacturers and wholesalers. For an owner, a banner brings purchasing, tools and marketing they cannot fund alone; it also creates contractual commitments the buyer will examine closely.
The cost and complexity of setting up. The average first-installation loan reached €1.36 million in 2025 according to Interfimo, up on the previous year. ⁴ Taking over a mid-sized pharmacy alone requires equity and debt that many young graduates cannot or will not carry. Structures with an established owner, gradual entry of an employed pharmacist into the capital or backing by a pharmacists' holding meet this constraint, and shift succession from the business to the shares.

Who takes over pharmacies today

Community pharmacy differs from other self-employed health professions by a simple rule: the capital of a company operating a pharmacy must be held by community pharmacists, and the owner who engages their diploma must remain the majority shareholder, directly or through their professional holding company (SPFPL), itself wholly owned by pharmacists. Employed pharmacists may enter the capital, and an owner may not hold stakes in more than four SELs other than their own. ⁸ Investment funds therefore cannot become shareholders of a pharmacy as they can of biology laboratories or imaging practices. This does not prevent outside capital from intervening, through debt, structured financing instruments or taking control of buying groups and banners, which the Senate fact-finding mission on the financialisation of healthcare noted in September 2024, citing a fund dedicated to pharmacies with strong commercial potential. ⁹ The professional order reaffirmed in January 2025 its commitment to professional independence and its intention to scrutinise structures. ¹⁰

Within this framework, there are four buyer profiles.

The young pharmacist setting up for the first time, often accompanied. They remain the most frequent buyer, but increasingly set up in pairs or with an experienced owner who provides part of the equity and guarantees. The quality of their financing and project is decisive for the bank and the seller. Women represent 56% of first-time buyers. ⁴
The established owner building a group of pharmacies. Through one or more SPFPLs, they buy a second, third then fourth pharmacy, entrust daily operations to minority practising partners or employed pharmacists with a stake, and pool purchasing, HR and management. This is now the most structuring movement in the market, particularly for mid-sized and large pharmacies.
The neighbouring peer in a merger logic. In areas where two nearby pharmacies are no longer viable separately, a purchase followed by a merger on a single site keeps a team and customer base, extends opening hours and accommodates new services, with specific aid provided by the pharmacy agreement. Some closures fall into this pattern. The analysis then goes beyond a simple sale: the new site, the combined team, authorisations and territorial logic must be thought through.
High-volume commercial pharmacies. Very high-volume shopping centre or town centre pharmacies, often under a banner, attract owners who already run several outlets and have the organisation to run them. The price of these pharmacies bears no comparison with that of a neighbourhood pharmacy, but the circle of buyers able to take them on is narrower.

Amendment 2 to the pharmacy agreement, signed in April 2026 by the health insurance fund and the pharmacy unions FSPF and USPO, also extended the annual aid capped at €20,000 for pharmacies alone in their town in under-served areas, which should concern nearly a thousand pharmacies in 2026. ³ This support does not transform the economics of a small pharmacy, but it weighs in a buyer's decision.

What this changes for the owner

The diversity of buyers translates into a diversity of structures. There is no longer a single way to hand over a pharmacy, but several, which answer different personal situations.

A full sale of the business or shares remains the model for an owner close to retirement. A share sale often allows a smoother transition, with a few months during which the seller can remain an employed pharmacist or minority partner while introducing the team and patients.
A partnership with gradual entry into the capital is for an owner, whatever their age, who wants to secure part of their wealth, lighten their operating load and organise succession over three to five years. They sell a minority or majority to an employed pharmacist, a young colleague or an established owner, then the balance at an agreed date.
Joining a group of pharmacies means selling a majority of the shares to a multi-pharmacy owner or their SPFPL while keeping a stake and practising on site. The seller benefits from the group's tools, purchasing and administrative support and shares in the value created at a later sale.
A leveraged capital reorganisation lets an owner monetise part of their shares by contributing or selling them to a holding they control, financed by bank debt, and bring in an employed pharmacist or partner. It is the pharmacy equivalent of an OBO-type deal, within the capital ownership rules.

Whatever the structure, buyers and their banks look at the same things. Two pharmacies of similar size can have very different prospects depending on location, team and patient catchment: size matters, but the readability of profitability and the strength of the environment matter more.

Real margin. Once expensive medicines and low-margin products are adjusted and the owner's pay normalised, operating profitability is what underpins price and bank financing, far more than reported revenue.
Activity structure. Share of prescriptions, self-medication, parapharmacy and services, trend in prescription numbers, share of fees and services in remuneration: this mix sketches the pharmacy's economic profile and its resilience to the next reforms.
Location and catchment area. Local demographics, nearby prescribers and their age, footfall, competition, urban projects: a pharmacy's commercial strength is read in its environment as much as in its accounts.
The team. Number of employed pharmacists and pharmacy technicians, tenure, training in vaccination and testing, ability to maintain opening hours and run the counter autonomously: a stable, trained team is an asset in its own right, easing the transition for the buyer and reassuring the bank.
Premises, lease and tools. Floor space, accessibility, a private consultation area for new services, automation, the commercial lease and its deadlines directly affect the pharmacy's potential and the timetable of a deal.
Contractual commitments and compliance. Buying group and banner contracts, with their terms and exit clauses, regulatory compliance, quality procedures and stock management are reviewed in every due diligence.
Realistic development levers. New services to roll out, stock optimisation, improved patient journey, a possible merger: a buyer values documented prospects, but is wary of assumptions that depend on uncertain authorisations.

You are thinking of selling: is this the right moment for you?

This is the first question we ask, and the answer is not the same for everyone. The right moment for a sale, partnership or joining a group is never automatically "right now", even in a market where candidates remain numerous for good pharmacies. It depends on two things: you, meaning your life plans, personal horizon and wealth objectives, and your pharmacy, meaning its ability to realise today all the value it holds. In practice, we encounter two situations.

Your pharmacy is almost ready. Margin is readable, fees and services are growing, the team is stable and trained, the premises meet standards and the lease is secure. Or you want your pharmacy to become part of a larger project, that of a structured group of pharmacies, sometimes leveraged, that brings tools, purchasing, expertise and the resources to absorb the changes in remuneration and services the profession is going through, which is reassuring for you and for your team. In this case, a few weeks of preparation are enough to structure the file, adjust the accounts, gather legal documents and go to market in good conditions. The current context, with many multi-pharmacy owners and potential partners, then works in your favour.
Your pharmacy needs time. Margin was hit by the loss of a nearby prescriber, a recent investment or an excessive weight of expensive medicines, new services are not yet deployed, the lease is expiring or the premises cannot accommodate a private consultation area, the banner contract includes heavy commitments. Selling in these conditions remains possible, but it means accepting a discount and less favourable terms. We will then tell you frankly that it is better to spend several months, sometimes a few years, working on these points, and we can support you through that phase before launching the transaction when you are truly ready.

The workstreams that make the difference in pharmacy are well known: clarify profitability by isolating expensive medicines and normalising the owner's pay, make activity data by category reliable, document headcount and rotas, develop fees and services to anchor value in the team and organisation rather than volume, secure the lease and medical environment, renegotiate or document buying group and banner contracts, update quality procedures and stock management, and prepare the legal side, notably moving to a company or creating a holding when the deal justifies it. Depending on your starting point, these workstreams take a few weeks or a few years.

The benefit of talking early, even if you are not sure you want to sell, is precisely knowing which of these two situations you are in, widening the choice of buyers and organising the transition, rather than deciding under the pressure of a departure, an unexpected approach from a peer or a health problem.

Facing buyers who take over several pharmacies a year, with a specialist accountant, lawyer and banker experienced in these files, an owner negotiating the sale of their only pharmacy alone is rarely on an equal footing. The value of a pharmacy is not just a headline price: it depends on the deal structure (business or shares, cash portion, earn-out, stake retained), the warranties requested, the future of the team, the seller's transition terms and the treatment of stock and cash. Two offers for the same amount can mean very different economic realities.

The role of an independent M&A adviser is to value the pharmacy objectively, identify all relevant buyers, multi-pharmacy owners, peers, employed pharmacists, accompanied young graduates, put them in competition in a structured and confidential process, and negotiate terms beyond price alone. This competition protects the seller: it lets them compare genuinely different projects and choose the one that fits their wealth objectives, their team and their patients.

Frequently asked questions

How does the sale of a pharmacy work in France?

The sale of a pharmacy follows several stages: preparing the file with adjusted accounts and legal documents, confidentially approaching buyers, offers, accounting and regulatory due diligence, negotiation of the agreement, the buyer obtaining bank financing, then formalities with the professional order and the regional health agency. It covers either the business or the shares of the professional practice company, which changes taxation, warranties and the transition.

Can an investment fund buy a pharmacy in France?

No, not directly. The capital of a company operating a pharmacy must be held by community pharmacists, the owner must remain the majority shareholder and a pharmacy SPFPL can only be owned by pharmacists. A fund therefore cannot become a shareholder of a pharmacy as it can of a biology laboratory or radiology practice. Outside capital intervenes only indirectly, through debt or buying groups and banners, under the professional order's supervision.

Should you sell the business or the shares of your pharmacy?

Business sales remain the majority, but share sales are growing with the spread of professional practice companies. Selling shares allows a smoother transition, where the seller can remain a minority partner or employed pharmacist for a few months, and eases the gradual entry of an employed pharmacist or peer into the capital. The choice depends on the existing legal structure, the seller's taxation, the buyer's situation and the warranties each accepts.

Can you sell your pharmacy and continue to practise in it?

Yes, and it is increasingly common. The owner can sell part of their shares to an employed pharmacist, a young colleague or a multi-pharmacy owner, keep a stake and continue practising on site, then sell the balance at an agreed date. This structure secures part of their wealth and organises succession over time, within the rule that the practising owner must hold the majority.

Who buys pharmacies today?

The young pharmacist setting up for the first time remains the most frequent buyer, increasingly accompanied by a partner or experienced owner. Established owners building a group of pharmacies through an SPFPL have become the most structuring movement in the market, alongside neighbouring peers in a merger logic.

How long does it take to hand over a pharmacy?

Between launching the process and signing, generally six to nine months: preparing the file, consulting buyers, due diligence, negotiation, the buyer's financing, then formalities with the professional order and the ARS. Upstream preparation can last from a few weeks to several years depending on the pharmacy's condition, and a transition period of a few months often follows the sale.

Why do some pharmacies merge?

In areas where two nearby pharmacies are no longer viable separately, merging on a single site allows teams and investments to be pooled, opening hours to be extended and new services to be offered in suitable premises. The pharmacy agreement provides aid for these operations. The project must include the choice of site, the combined team and the necessary authorisations.

Why put several buyers in competition to sell your pharmacy?

Because offers differ on much more than price: sale of business or shares, cash portion, stake retained, takeover of stock, warranties, the future of the team and length of the transition. Consulting multi-pharmacy owners, peers and accompanied young graduates in parallel allows genuinely different projects to be compared on a like-for-like basis and strengthens the seller's negotiating position.

Public sources consulted

IGAS et IGF, Rapport sur la chaîne de distribution pharmaceutique et l'économie de l'officine (janvier 2026, publié mai 2026) : https://www.igas.gouv.fr/sites/igas/files/2026-05/Rapport%20IGAS-IGF%20chaine%20de%20distribution%20pharmaceutique%20%282026%29.pdf (high reliability)
Ordre national des pharmaciens, communiqué « Démographie des pharmaciens » (5 juin 2025) : https://www.ordre.pharmacien.fr/mediatheque/fichiers/communiques-de-presse/cp-demographie-des-pharmaciens (high reliability)
Caducée, Avenant 2 pharmaciens : 20 000 euros pour freiner les fermetures d'officines fragiles (avril 2026) : https://www.caducee.net/actualite-medicale/16876/avenant-2-pharmaciens-20-000-euros-pour-freiner-les-fermetures-d-officines-fragiles.html (good reliability)
Interfimo, Le prix des pharmacies en 2025 (étude 2026) : https://www.interfimo.fr/files/blog-post/de/2026-interfimo-prix-des-pharmacies-en-2025.pdf (good reliability)
Ordre national des pharmaciens, communiqué « 10 ans d'évolutions démographiques pour la profession de pharmaciens » (17 juin 2026) : https://www.ordre.pharmacien.fr/mediatheque/fichiers/communiques-de-presse/cp_10-ans-d-evolutions-demographiques-pour-la-profession-de-pharmaciens_17.06.2026 (high reliability)
Ordre national des pharmaciens, Les pharmaciens : panorama au 1er janvier 2026 : https://www.ordre.pharmacien.fr/les-communications/focus-sur/la-demographie/les-pharmaciens-panorama-au-1er-janvier-2026 (high reliability)
Le Quotidien du Pharmacien, Plus d'une pharmacie sur sept affiliée à l'une des sept principales enseignes (décembre 2025) et Plus de 9 pharmaciens sur 10 adhèrent à un groupement (mars 2023) : https://www.lequotidiendupharmacien.fr/exercice-pro/plus-dune-pharmacie-sur-sept-affiliee-lune-des-sept-principales-enseignes (good reliability)
Ordre national des pharmaciens, Dossier « Se grouper dans des structures juridiques : SPFPL et SEL, y voir plus clair » (2014) : https://www.ordre.pharmacien.fr/mediatheque/fichiers/documents-fiches-professionnelles/dossier-se-grouper-dans-des-structures-juridiques-spfpl-et-sel-y-voir-plus-clair (high reliability)
Sénat, Rapport d'information sur la financiarisation de l'offre de soins, C. Imbert, B. Jomier, O. Henno (25 septembre 2024) : https://senat.fr/rap/r23-776/r23-7761.pdf (high reliability)
Ordre national des pharmaciens, La financiarisation de l'offre de soins : les enjeux pour la pharmacie, lettre institutionnelle n° 21 (janvier 2025) : https://www.ordre.pharmacien.fr/mediatheque/fichiers/documents-pages/la-financiarisation-de-l-offre-de-soins-les-enjeux-pour-la-pharmacie (high reliability)